Establishment Labs (ESTA) Earnings Transcript

Image source: The Motley Fool.

DATE

Wednesday, Nov. 5, 2025 at 8:30 a.m. ET

CALL PARTICIPANTS

Chief Executive Officer — Fillipo Peter Caldini

Chief Financial Officer — Rajbir Denhoy

Need a quote from a Motley Fool analyst? Email pr@fool.com

TAKEAWAYS

Total Revenue -- $53.8 million, representing a 33.7% increase year-over-year; excluding foreign exchange, growth would have been approximately 31.4%.

Gross Profit Margin -- Achieved 70.1%, surpassing the 70% threshold for the first time, up 620 basis points from last year, and 130 basis points sequentially from the prior quarter.

United States Revenue -- $11.9 million, up 16% sequentially from the previous quarter, despite Q3 typically being seasonally low for breast procedures.

Positive adjusted EBITDA -- Reached $1.2 million, marking the company’s first quarter of positive adjusted EBITDA; compared to losses of $8.5 million and $12.1 million in the previous two quarters, respectively.

2025 Revenue Guidance Raised -- Now expects revenue to exceed $210 million, updating prior guidance of $208 million to $212 million, representing a minimum growth outlook of 26%.

Direct Market Growth (Outside U.S.) -- Direct markets grew 15% year-over-year, excluding Benelux acquisition and currency effects; European direct market sales increased approximately 20%.

Asia-Pacific Sequential Growth -- Region delivered 46% sequential growth as distributor orders normalized from the previous quarter.

Minimally Invasive Portfolio -- Approximately 300 procedures performed in the U.S. with the PRESIVE kit from initial launch; at least 100 women are on procedure waitlists countrywide.

Accounts Using Motiva -- Over 1,300 surgeons now use Motiva products in the United States, including leading high-volume practices.

Cash Position -- Ended the quarter with $70.6 million in cash, an increase from $54.6 million in the prior quarter, primarily due to drawing $25 million from the credit facility, offset by operating cash use.

Operating Expenses -- Totaled $41.7 million, an increase of approximately $2.9 million over the prior year, but more than $5 million below 2023.

U.S. Market Share Target -- Management expects to reach approximately 20% share of the U.S. breast augmentation market by year-end, with ongoing growth anticipated.

2025 Gross Margin Outlook -- Gross margin for the year is expected to be about 300 basis points higher than in 2024.

Cash Flow Goals -- Company expects to be cash flow positive in 2026 without further equity raise requirements.

Minimally Invasive Portfolio 2026 Target -- Management stated, "Globally, we expect a portfolio of NIA and PRESIVE will exceed $30 million in 2026."

SUMMARY

Establishment Labs Holdings (NASDAQ:ESTA) reported its first-ever quarter of positive EBITDA, driven by accelerating U.S. breast aesthetics and direct market segments, which contributed to both revenue growth and improved gross margins. Operating expense control and increased utilization among high-volume Motiva accounts enabled a rapid shift to profitability, while strategic investments in commercial infrastructure are largely complete. Demand for the minimally invasive platform is evidenced by several hundred U.S. cases performed and significant procedure waitlists, supporting a major topline target for that segment in 2026. The cash position was strengthened without dilutive equity action, and management reported improved operating cash trends, citing a pathway to positive company-wide cash flow by next year.

Chief Executive Officer Caldini emphasized, "we are going to be prudent by raising our 2025 revenue guidance to exceed $210 million."

Rajbir Denhoy commented, "We expect EBITDA will continue to improve, including in the fourth quarter, and expect to remain EBITDA positive from here on."

Management referenced a "combination of continued growth in the accounts that we are in," new account additions, and upcoming product launches as core to sustaining U.S. momentum in 2026.

Breast reconstruction market entry and approval timelines remain in focus, with ongoing preparation for a U.S. launch and regulatory milestone filings anticipated by year-end.

INDUSTRY GLOSSARY

Motiva: The flagship line of silicone gel‑filled breast implants used in aesthetic surgeries.

PRESIVE (also cited as PRESIVA, PRESURVAY, or PRESYVAY): The company's minimally invasive, breast tissue-preserving surgical platform designed for reduced scarring, faster recovery, and a premium price versus standard procedures.

Direct Markets: Countries where the company sells directly rather than through third-party distributors.

Fluor Tissue Expander: An implantable device used to expand breast tissue before reconstruction surgery, currently in use at over 150 U.S. hospitals.

NIA: Reference to a product or portfolio segment within the company's minimally invasive offerings, specifically cited in the context of 2026 revenue targets.

Full Conference Call Transcript

Rajbir Denhoy: Thank you, operator, and thank you, everyone, for joining us. With me today is Fillipo Peter Caldini, our Chief Executive Officer. Following our prepared remarks, we will take your questions. Before we begin, I would like to remind you that comments made by management during this call will include forward-looking statements within the meaning of federal securities laws. These include statements on Establishment Labs Holdings Inc.'s financial outlook and the company's plans and timing for product development and sales. These forward-looking statements are based on management's current expectations and involve risks and uncertainties.

For a discussion of the principal risk factors and uncertainties that may affect our performance, or cause actual results to differ materially from these statements, I encourage you to review our most recent annual and quarterly reports on Form 10-Ks and Form 10-Q as well as other SEC filings, which are available on our website at establishmentlabs.com. I would also like to remind you that our comments may include certain non-GAAP financial measures with respect to our performance, including but not limited to sales results, which can be stated on a constant currency basis or EBITDA, which we disclose on an adjusted EBITDA basis.

Reconciliations to comparable GAAP financial measures to non-GAAP measures, if available, may be found in today's press release, which is available on our website. The content of this conference call contains time-sensitive information accurate only as of the date of this live broadcast, 11/05/2025. Except as required by law, Establishment Labs Holdings Inc. undertakes no obligation to revise or otherwise update any statement to reflect events or circumstances after the date of this call. With that, it is my pleasure to turn the call over to Peter.

Fillipo Peter Caldini: Good morning to everyone and thank you for joining today. Q3 2025 was a standout quarter for Establishment Labs Holdings Inc. We grew global revenue 34% with total revenue of $53.8 million, including $11.9 million in the U.S. We also exceeded a 70% gross profit margin for the first time, coming in at 70.1%. We achieved the first quarter of positive EBITDA in our company's history, with $1.2 million in Q3. Getting to positive EBITDA ahead of the fourth quarter was an important goal for our company, and we now turn our focus towards reaching cash flow positive next year. While optimizing our business, we had meaningful revenue growth in the U.S. and our other direct markets.

I would like to thank all the employees that made this a priority and a reality, and the sense of accomplishment has all our employees eager for our next milestone of cash flow positive. The U.S. business is our most important growth segment right now, and it continues to outperform. Q3 revenue was $11.9 million, up 16% sequentially in what is a seasonally slower quarter in breast procedures. Markets can be down 20% to 30% sequentially in Q3, making our results all the more impressive. For the first three quarters, U.S. revenue totaled $28.3 million, so we are clearly going to do quite a bit better than the $40 million we committed to last quarter.

We are expecting considerable acceleration of the U.S. business, and we are already seeing a significant shift from Q3. But as it is our first full Q4, we are going to be prudent by raising our 2025 revenue guidance to exceed $210 million, where we previously had a range of $208 million to $212 million. Most interesting is what these results imply for 2026, because we should finish 2025 with an approximate 20% share in the U.S. breast augmentation market, and the momentum has not slowed.

While 2026 will be a continuation of our growth in the breast augmentation segment, we are looking forward to our approval in breast reconstruction, which is similar in market size to augmentation, and we are preparing for the U.S. launch in this segment. Outside the U.S., we saw good growth and remain on track for single-digit growth this year. Accelerating growth in our direct markets has been a priority, and we are seeing the benefits of the changes we have implemented. Excluding the benefit of currency and the acquisition of our Benelux distributor, our European direct market sales increased approximately 20% this quarter over Q3 2024.

In our distributor markets, Asia Pacific had a strong rebound from the second quarter as the ordering cadence normalized. Our U.S. business is performing at a very high level. The number of surgeons using Motiva continues to increase. We now have over 1,300 surgeons using Motiva, including some of the highest volume and best-known practices in the country, and we are attracting additional waves of adopters as the benefits of Motiva in both clinical and commercial practice resonate.

Rajbir Denhoy: We are focused on surgeons making Motiva their primary implant of choice as we are at attracting new surgeons to our business. We continue to bring groups of surgeons down to Costa Rica for training and surgery. Over 50 surgeons attended our September and October classes, and more than 250 surgeons have come to Costa Rica since launch. We are expecting a similar pace in 2026, with seven sessions already scheduled. There is no shortage of surgeons that want to make the trip. Surgeons learn about the science behind our implant technology, see the best-in-class standards employed throughout our facilities, and experience our commitment to driving innovation in the category, including discussing and offering input to our R&D pipeline.

While some surgeons come already enthused about Establishment Labs Holdings Inc., almost every surgeon returns to their practice as a fan of our company. Social media continues to play an important role as plastic surgeons advocate Motiva to their audiences. Plastic surgeons consistently tell us that if they offer patients a choice between Motiva and legacy implants, it is almost unanimous that patients will choose Motiva. This puts us in a position of strength, and we win if we convince plastic surgeons to give patients a choice. Every legacy brand has a much more challenging proposition. They have to convince plastic surgeons to offer only their products.

Championing women's health and advocating for patients' choice should accelerate us to take a majority of the U.S. market over the next several years. In Q3, we conducted a survey of surgeons that are early adopters and advocates of Motiva to understand the impact of Motiva on their practices. While industry sources point to a market that has not experienced much growth, the practices offering Motiva in our survey increased their procedures by 14.6% so far this year. Surgeons tell us that patients are coming in and asking for Motiva by name. And we hear from surgeons as well that many women are entering the category because of Motiva.

We regularly hear that women are abandoning their warranty of their legacy implants and choosing to pay out of pocket for Motiva. As many of you know, this is incredibly rare in healthcare. But it is happening now as our entry is changing the industry. There is not just one single reason for this. Some women cite the improved safety profile offered by Motiva, and others cite the benefits of having an above-the-muscle procedure without compromise. And yet for others, it is the increased awareness from our marketing efforts. Whatever the reason, it is clear the conversation around breast augmentation is changing. This is a powerful combination.

We are not only capturing share, but we are expanding and accelerating the market for breast augmentation.

Fillipo Peter Caldini: A major driver for market expansion is our minimally invasive portfolio. As we have noted, we trained a group of U.S. plastic surgeons in July as part of our early experience group for Preserve to gain insights prior to going to market more broadly. PRESUVEY is a breast tissue-preserving procedure that can be done without the need for general anesthesia, offering smaller scars and fast recovery. Preservaix can be used in a wide cross-section of cases, surgency, in their day-to-day practices. As these surgeons have taken Preservaes back to their practice and started to perform procedures, the feedback has been very positive, not only from surgeons but also from the women who have received the procedures.

I encourage you to seek out the videos and testimonials that have been posted on our social media to see the early responses. Surgeons have embraced the fundamental changes PRESIVRAY brings to breast augmentation. It is not just a new way to do an existing procedure; it is an entirely new concept in how a breast procedure can be done. PRESIVE has the potential to drive category growth and improve the economics for surgeons. We are seeing as much as a 40% price premium to a standard breast augmentation for these early experienced surgeons. The group of surgeons that came for PRESIVAY training were each supplied a small number of kits in August.

A majority of the kits we provided have been used, and surgeons consistently ask us for more to alleviate growing waitlists. From just our early experience launch, we would estimate that 300 PRESIVE cases have been performed in the U.S., and there are at least 100 women on waitlists around the country. Not expectedly, there is a groundswell of surgeons that have asked to be trained on PRESYVAY, and we will begin these trainings in January. We have two such trainings planned for the first quarter alone and would expect a similar cadence throughout the year. In breast reconstruction, our Fluor Tissue Expander is now in use at over 150 hospitals in the United States.

This bodes well for the expected launch into reconstruction. We remain on track to file our PMA supplement by the end of the year. We also remain on track for the approval of our small sizes in the U.S. in early 2026, and this should help accelerate growth both with new doctors as well as increasing the usage of our current doctors.

Rajbir Denhoy: Outside the U.S., excluding the benefit of our Benelux acquisition and currency, direct markets globally grew 15% versus last year. We believe this performance is well above the underlying market growth rates in these regions. In our Latin American direct markets, we continue to see stabilization in Brazil and strong growth in Argentina. European direct markets are being led by strong performances across the continent with standouts in the UK and Spain. The number of accounts in many of our direct countries continues to increase, a positive sign and a reflection of the increased focus on performance in direct markets.

We are taking advantage of our strong growth in direct markets to make sure that the OUS business as a whole is primed for growth. We are engaging with our distributor partners regularly. We are working to raise standards globally around payment terms, inventory forecasts, and market share expectations. In our minimally invasive portfolio, EMEA remains on track to achieve $8 million to $10 million in revenue in 2020, and PRESURVAY continues to see good adoption in international markets. Surgeons globally are seeing the benefits of breast tissue preservation made possible by our minimally invasive platform. The successful rollout of Preserve and the continued growth of Mia has resulted in above-market growth and proves its potential for market expansion.

Globally, we expect a portfolio of NIA and PRESIVE will exceed $30 million in 2026. I will now turn the call over to Raj.

Rajbir Denhoy: Thank you, Peter. Total revenue for the third quarter was $53.8 million, an increase of 33.7% from last year. Excluding the positive impact of foreign exchange in the quarter, growth would have been approximately 31.4%. Sales for Motiva in the United States were $11.9 million. On a geographic basis, sales in Europe, Middle East, and Africa were 35.6% of the global total, saw strong sales in our direct markets in the region, sales to distributors were lower on the timing of orders. Sales in the United States were 22.1% of the global total, Latin America was 21.7% of sales.

Brazil remained stable, and we saw strong growth in our other direct market in the region, Argentina, as well as from our distributors. Asia Pacific was 20.6% of sales. Results in the quarter rebounded sharply from last quarter as expected orders from our distributors were realized. Sequential growth in the region was 46%. Our gross profit for the third quarter was $37.7 million or 70.1% of revenue, a 620 basis point increase compared to 63.9% of revenue last year, 130 basis points higher than the 68.8% in the second quarter of this year. This is the first time we have crossed a 70% gross margin. And the increase is primarily the result of higher margin sales in the United States.

We expect gross margins in 2025 will be approximately 300 basis points higher than in 2024. As it relates to tariffs, goods imported from Costa Rica to the United States are subject to duties. However, as we saw in 3Q, we are managing their impact and do not meaningfully change our trajectory for gross margin improvements this year. SG&A expenses of $37.2 million were approximately $3.1 million higher than in 2024. R&D expenses for the third quarter were $4.6 million. Total operating expenses for the third quarter increased approximately $2.9 million from the year-ago period, to $41.7 million.

Operating expenses have been approximately $45 million to $46 million on average per quarter, which is what we guided to at the start of the year and what we continue to expect. As we saw in this quarter and in the second quarter, there can be fluctuations based on the timing of expenses. Adjusted EBITDA was positive $1.2 million in the third quarter. This compared to a loss of $8.5 million in the second quarter and $12.1 million in the first quarter. This is our first EBITDA positive quarter as a company, and there are a couple of things to highlight.

While the improving results are being supported by the strong sales and the higher gross profit in the United States, we have been very focused on managing our operating expenses. While operating expenses in the third quarter increased approximately $3 million from a year ago, they were down over $5 million from 2023. Over the time, we invested significantly in our U.S. commercial operation and launched our minimally invasive portfolio. We were able to do this by finding efficiencies across all parts of the organization and making structural changes where needed. We expect EBITDA will continue to improve, including in the fourth quarter, and expect to remain EBITDA positive from here on.

For 2026, we will continue to expand our commercial infrastructure in the United States. However, the investments we make overall as a company will be at a rate well below expected top-line growth. We have been investing with the expectation of global market leadership and have built an organization that can take full financial and commercial advantage as that occurs. Most of our spending in this regard has already happened. For example, the facilities we have today can produce more than half the world's implants. We expect revenue to grow more than 20% for at least several more years, and our business should start to show meaningful and increasing earnings in 2027 and beyond.

Cash increased $616 million in the third quarter to $70.6 million from $54.6 million at the end of the second quarter. The increase was primarily the result of drawing the remaining $25 million tranche of our credit facility offset by our operating cash fees. Excluding the net proceeds, use would have been $8.5 million in the third quarter. This compares to $14.5 million in the second quarter and $21.2 million in the first quarter. We expect cash used to improve further in the fourth quarter and expect to reach cash flow positive in 2026 without the need for any further equity raises. Our credit facility won the last year of its term in April.

We are considering a number of refinancing options that could further reduce our cash use. We are also working to make ESTA eligible for inclusion in a number of indices, most notably the Russell. There are a number of things we can do to affect this, and we believe we will be eligible for future rebalancing. As Peter noted, we now expect our revenue in 2025 will exceed $210 million, an upward revision from our previous guidance of $208 million to $212 million. Our updated outlook represents growth of at least 26%. The U.S. remains a primary engine of growth this year. We have seen very strong results over 2025, and this has continued into the fourth quarter.

Our direct markets outside the U.S. are also doing well, and demand globally for our products remains good. Gross margins are improving, and we are managing our operating expenses, which allowed us to achieve positive EBITDA a quarter early. Expect to see continued improvements in profitability and remain confident we will reach cash flow positive in 2026. I will now turn the call back to Peter.

Fillipo Peter Caldini: 2025 was in many ways a turning point for our company. We achieved positive EBITDA for the first time, and we achieved this in a quarter where we grew revenue 34%. These results show that we can efficiently invest in and grow our business, and we will continue to do so. The next step is to achieve cash flow positive, which I am confident we will do next year. We expect our top-line growth to remain above 20% for the next several years, and our profitability should expand at a much faster pace.

I am looking forward to having conversations with our shareholders about our increasing EPS and how we can keep that momentum going for the next five to ten years. Operator, we are ready to take questions.

Operator: Thank you. At this time, we will conduct a question and answer session. The first question comes from Anthony Petrone with Mizuho. Please proceed.

Anthony Petrone: Thanks and congrats to the team all around here on strong execution. Maybe Pete and Raj, you could start with the comments on 2025 and just the implied outlook as we head into the end of the year. Now just looking for some more inputs and takes on that 4Q number specifically, how should we think about OUS trends? Obviously, there is strong momentum on the U.S. side. But maybe a little bit more detail on what we are thinking about new account openings from here, Preserve uptake? And then lastly, just the EBITDA positive well ahead of expectations. How do you think about EBITDA trending from here just given the momentum on the U.S. side? Thanks again.

Rajbir Denhoy: Yeah. Thanks for the question, Anthony. Clearly, a lot of momentum in the business heading into the fourth quarter, and as we noted, we are trying to exceed $210 million now for the year. As it relates to the fourth quarter, the U.S. has quickly become our largest market, and we have a lot of momentum in the U.S. For us though, we have not yet seen a fourth quarter, right? And there are some nuances in the fourth quarter around reconstruction and some of the holidays and things. And so we just want to be prudent in terms of how we set the midpoint for the fourth quarter.

But clearly, we have a lot of momentum and expect to meaningfully exceed $40 million we previously provided. And so the U.S. is doing very well. Outside the U.S., we also have a lot of momentum, specifically in direct markets where we are seeing very strong growth. In Europe, we were north of 20% in direct markets this quarter. We have a really strong order book for the fourth quarter from our distributors. And so we are expecting a very strong finish to the year. And I think importantly, that sets us up really well for 2026, right?

The momentum we are carrying in the business that will play forward in next year really is a nice place to be as we are entering the New Year. As it relates to EBITDA, again, we are all very proud of what we have achieved here a quarter early, the $1.2 million. But as we also noted, it is just the beginning here, right? We have a lot of leverage we can still bring through this business as we are investing. And you will see EBITDA continue to expand in the fourth quarter, and we expect to continue to show nice improvements overall in 2026. And so I think the business again has a lot of momentum.

We are starting in the profitability, the leverage in the model. And we expect that is going to continue from here forward.

Anthony Petrone: Appreciate that. I will hop back in.

Operator: The next question comes from Joshua Jennings with TD Cowen. Please proceed.

Joshua Jennings: Hi, good morning and congratulations on arriving in the EBITDA positive era a little bit earlier than expected. Pete and Raj, I was hoping to just start on the thinking about 2026 and international business, but specifically, China. Any updates just in terms of the outlook there and the distributor relationships and when reordering could start to kick in, which should we be expecting Q1 2026? Is there any chance that there could be some China orders in the fourth quarter?

Fillipo Peter Caldini: Yes. So thank you, Josh. In terms of the OUS markets, I think in general, we have seen stabilization for the most part across all the markets. Our focus going into this year, Josh, was really driving growth in our direct markets. And I think we have been very successful in doing that. We have better economics. We have more upside potential in those markets. And as Raj mentioned, we had 20% growth, and that is following a quarter where we had 27% growth in our European markets. So organic accounts, a lot of that growth is being fueled by Preserve, but very strong performance, and we are going to continue to focus on that going into 2026.

And we see good momentum in the fourth quarter, and that is going to continue into next year. Yeah. As it relates to China, I think we are working very closely with our partners there. We have actually seen some good progress, especially from a sellout standpoint, and we are going to continue to work closely with them, and we are going to keep you updated, but we want to make sure we build the business there the right way.

Operator: Thank you. The next question comes from Allen Gong with JPMorgan. Please proceed.

Allen Gong: Thanks for the question. I have one on the broader market. When we look to some of your peers in aesthetics, I think some of the body language we were getting from them was definitely a bit more cautious on market dynamics, especially heading into the fourth quarter. Looking at your results and listening to your confidence, definitely sounds like you are not seeing that. So I guess, you know, are you not seeing that weakness? Are you just growing through it? Or is there a reason why those challenges are more company-specific than for the broader market?

Fillipo Peter Caldini: Yes, thanks. First, I mean, I cannot really comment on their perspective in terms of the I can just tell you how we are seeing the market in the U.S. Specific to breast aesthetics, I think we have created a lot of momentum in the marketplace. And I think what we mentioned in the prepared remarks, in some of the accounts that have early in Motiva, we are seeing an increase in the number of procedures. So what we are seeing as it relates to our business, we are seeing growth. We are very positive in terms of the momentum we have been able to build in Q4, and that is just going to continue into next year.

Operator: The next question comes from Sam Shimon Eiber with BTIG. Please proceed.

Sam Shimon Eiber: Hi, good morning. Thanks for taking the questions. Maybe I can shift over to the minimally invasive platforms. You talked about the $30 million revenue for next year. Can you just maybe help frame contribution this year? If there is any way to parse out EMEA versus Prezurve? And then what market development work needs to happen to get to those at least $30 million target for next year? Thanks for taking the questions.

Fillipo Peter Caldini: Yes. Thanks, Sam. We are very happy with the progress we are making with PRESIVE and the minimally invasive platform. Speaking specifically on new, we have doubled the number of accounts this year, and that was our goal. And then with Prezave, we are off to an outstanding start in Europe. And we are really focusing primarily in the direct markets, but we are also expanding into some of our distributor markets. And that momentum is going to continue into 2026. We mentioned also that in the U.S., we are going to be launching early part of next year. So we are looking at the end of the first quarter. There is already significant demand.

We have seen that with the early experienced surgeons. They are very excited. And I think once it is launched, I think it is going to be a pretty quick ramp-up. So we are very pleased with that platform and how it is performing.

Operator: The next question comes from Joanne Wuensch with Citi. Please proceed.

Anthony Charles Petrone: This is Anthony filling in for Joanne. Thanks for taking the question. Is there any chance you could provide to either quantify or maybe provide a little bit more granularity around your expectation for U.S. sales to meaningfully exceed $40 million this year?

Rajbir Denhoy: Yes, Anthony. As I tried to answer the first question, the fourth quarter again is we are carrying a lot of momentum into the fourth quarter, right. And so we will do quite a bit better than the $40 million we have previously talked about. However, it is the first time we have had a fourth quarter in the United States, right? And so there are some holidays, some other elements in the quarter that make it difficult to kind of tell you exactly where we are going to land. And so again, it is a difficult question, but I think the reality is we are doing very well in the U.S.

Number of accounts, the orders we are getting, all of it is really pushing in the right direction. And we just we simply have a lot of momentum that we are carrying right now.

Operator: The next question comes from Mason Owen Carrico with Stephens. Please proceed.

Mason Owen Carrico: Hey, thanks for taking the question. So reiterating single-digit growth in international revenue, it seems like you are seeing strength across a handful of markets. Stability in others. Are you willing to quantify how at least preliminarily you are thinking about growth in the international market next year?

Fillipo Peter Caldini: Yeah. I think, Mason, it is a good question, right? We have not yet provided the 2026 outlook. But from a high-level standpoint, we are seeing very good demand in our direct markets. It has been an area of focus for us. We spent a lot of time making sure we have the right team there, the right structure there. And you are seeing that play out now, and we do not expect that momentum will slow. And so that is going to carry us into 2026. The other part of the business is distributors. We do not have perfect visibility into how the distributors are doing. But generally, the tone in those markets remains very good.

The end markets seem very similar to what we are seeing in our direct markets. And so overall, we are expecting in 2026, our international markets will perform well. And then you marry that with what we are seeing in the United States, and we commented we expect to finish it at approximately 20%, which provides a very good stepping-off point in the U.S. for 2026. And overall, we are expecting another year of very strong growth for the company.

Mason Owen Carrico: Got it. Okay. And in terms of Motiva accounts in the U.S., what are you guys seeing in terms of trends among customers after adoption? How quickly are you seeing them ramp up? Is there an average amount of their practice they end up converting? Any incremental detail you can provide there?

Fillipo Peter Caldini: Yeah. I think as we mentioned before, the growth in the U.S. is really exceeding all our expectations. We have kind of over-delivered on most of the internal KPIs that we have. So we are very pleased with that. We continue to add additional accounts. The utilization rate continues to pick up, especially as a lot of the accounts are going through their scheduling process. What also helps quite a bit in terms of the utilization and also the penetration is the number of patients that are entering the accounts asking specifically for Motiva.

So we are seeing really good growth in Q4, and it is somewhat of an inflection point for us, and we believe that momentum will finish this year and then it is going to continue to grow next year, especially when we start layering over some of the Preserve launch, also the small sizes as well.

Mason Owen Carrico: Got it. Thank you.

Operator: The next question comes from Mike Matson with Needham and Company. Please proceed.

Mike Matson: Yes, thanks. So I wanted to get some clarification on the commentary around getting to 20% share exiting the year. So we had estimated that the U.S. market augmentation market is around $600 million, so about $150 million a quarter if you flatline it. And 20% of that would sort of imply about $30 million. I mean, is that math reasonable? Or am I missing something? Maybe you mean like as of the very last day of the quarter, you will be at it is ramping through the quarter, and you will be at 20% as of the very tail end of the quarter or something like that.

Rajbir Denhoy: Yes, Mike. I think just to level set, I think your expectation for the size of the market may be a little bit off. If you look at some of the data from the clinical societies, the market in the United States is estimated at approximately 100,000 procedures a year. Our ASPs we have talked about are around $1,300, a little north of $1,300 per case. That puts you at a little bit below $400 million for the augmentation market. The reconstruction market is a market about that same size, right? So if you just think about the augmentation market, you are looking at a market close to $390 million to $400 million in that range.

And that is the market against which we expect to exit at about 20%.

Mike Matson: Okay. So more like a $20 million number then?

Rajbir Denhoy: But again, that is also an exit rate, right? As we are leaving 2025.

Mike Matson: Okay. All right. Understand. And then just as far as the April goes, how much visibility do you feel you have? I mean, we are over a month into the quarter now or I guess, sorry, two months into the quarter now. And then I know you have orders that you get, and so I do not know how much lead time there is between the order and the shipment and things like that.

Rajbir Denhoy: Well, we do. I mean, we do see the daily orders, right? We know the number of customers we have. And so we have quite a bit of visibility in how the business is tracking. And as we noted, there is a lot of momentum right now. Those metrics all continue to go higher. And as we are leaving the third quarter and we have entered the fourth quarter here, moving out of that seasonally slow period, there is a lot of acceleration in this business. Again, it is our first fourth quarter as a company in the United States.

And so we just want to be prudent in terms of where we set the midpoint of where we think we end up. But you should not think that there is anything behind that, right? The business is doing extremely well, and we are going to have a very strong finish to the year.

Mike Matson: Okay. Understand. Thanks.

Operator: The next question comes from Matthew Charles Taylor with Jefferies. Please proceed.

Matthew Charles Taylor: Hi, good morning. This is Matt on for Matt Taylor. I just wanted to ask a quick question on 2026. And assuming you are exiting 2025 with around 20% market share, looking at your kind of strategy into next year, do you anticipate driving your expansion primarily through penetration with these existing accounts? Or is it mainly blocking and tackling going after new accounts?

Fillipo Peter Caldini: Yeah. So, I mean, as we mentioned before, I mean, we are exiting 2025 with tremendous momentum. We keep on adding existing accounts or adding accounts. The utilization rate continues to pick up. And that momentum is going to continue into next year. Now what we are also doing is we, and we mentioned this on the previous call, we are going to be adding reps up to about 15 reps for next year. And that will help increase the utilization, also the reach in some of those accounts that we can add into next year.

We are also going to be launching Preserve at the end of the first quarter, and then we also have the launch of the small size of which we anticipate the beginning of next year. So I think you are going to see a combination of continued growth in the accounts that we are in, and as we continue to increase the utilization rate, we are going to be adding additional accounts. And then you also have with the expansion in terms of filling out our matrix as well as with the PRESIVA launch. I think you are going to see a combination of both.

Matthew Charles Taylor: Okay. That is helpful. So I would say, like, looking at your five-year plan, you are still fairly confident in kind of reaching that goal of, I do not know, 40% to 70% that you have seen in other markets? Is that fair to assume?

Fillipo Peter Caldini: Yes.

Operator: Yes. Okay.

Rajbir Denhoy: Thank you.

Operator: Thank you. This is all the time we have for questions today. I will now turn the call back to Fillipo Peter Caldini for closing remarks.

Fillipo Peter Caldini: Okay. Thank you, everybody, for joining. Look forward to the next call, and thank you very much for attending.

Operator: This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation and have a great day.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.